Scarica l'app Stockscreener
94.45
4.07%
-4.01
Dopo l'orario di chiusura:
94.50
0.05
+0.05%
Precedente Chiudi:
$98.46
Aprire:
$98.95
Volume 24 ore:
2.67M
Relative Volume:
1.83
Capitalizzazione di mercato:
$5.94B
Reddito:
-
Utile/perdita netta:
$-230.66M
Rapporto P/E:
-22.63
EPS:
-4.1742
Flusso di cassa netto:
$-148.12M
1 W Prestazione:
+191.96%
1M Prestazione:
+151.87%
6M Prestazione:
+132.46%
1 anno Prestazione:
+603.28%
Intervallo 1D:
$88.63
$98.95
Intervallo di 1 settimana:
$60.49
$104.00
Portata 52W:
$10.94
$104.00
Kodiak Sciences Inc Stock (KOD) Company Profile
Nome
Kodiak Sciences Inc
Settore
Industria
Telefono
650-281-0850
Indirizzo
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
94.45 | 2.03B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Iniziato | Jefferies | Buy |
| 2025-08-14 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2023-12-11 | Ripresa | Goldman | Sell |
| 2023-11-17 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-07-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-15 | Iniziato | CapitalOne | Overweight |
| 2022-08-02 | Downgrade | Citigroup | Neutral → Sell |
| 2022-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2022-02-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Iniziato | Evercore ISI | Outperform |
| 2021-03-01 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-11-30 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-03 | Iniziato | Goldman | Buy |
| 2020-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Iniziato | SunTrust | Buy |
| 2020-01-08 | Iniziato | ROTH Capital | Buy |
| 2020-01-03 | Iniziato | Jefferies | Buy |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-20 | Iniziato | Chardan Capital Markets | Buy |
| 2018-10-29 | Iniziato | Barclays | Overweight |
| 2018-10-29 | Iniziato | BofA/Merrill | Buy |
| 2018-10-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com
Why is Kodiak Sciences stock rallying today? - Investing.com
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria
Kodiak Sciences stock clears a major clinical hurdle - AD HOC NEWS
Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo
A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan
Kodiak Sciences Inc. (KOD) Stock Price, News, Quote & History - Yahoo! Finance Canada
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $96 - Moomoo
Goldman Sachs Maintains Kodiak Sciences(KOD.US) With Hold Rating, Announces Target Price $103 - Moomoo
EBITDA margin % of Kodiak Sciences, Inc. – HAN:K27 - TradingView
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Australia
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - TradingView
Kodiak Sciences (KOD) Surges 138% in September Amid Strong Insider Buying and High Price-to-Sales Ratio - GuruFocus
H.C. Wainwright raises Kodiak Sciences stock price target on trial data - Investing.com Nigeria
Results are due Monday from a study of two potential treatments for an age-related eye disease. - Stock Titan
Biotech Stock Kodiak Sciences (Nasdaq: KOD) Leads Nasdaq's Monday Gainers; up 177% - Investorideas.com
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingView
New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs - Yahoo Finance
KODIAK SCIENCES INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $96 FROM $58 - webull.com
Why Kodiak Sciences Skyrocketed Today - theglobeandmail.com
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ - Yahoo Finance
MDB, KOD, NVTS, BA, NVDA: 5 Trending Stocks TodayNVIDIA (NASDAQ:NVDA) - Benzinga
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial - Yahoo Finance
Kodiak Sciences (KOD) Rockets As Phase 3 Catalysts Loom - StocksToTrade
Kodiak Sciences KOD Stock Soars Toward $100 After Strong Phase 3 DAYBREAK Trial Data - FXLeaders
Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea - Barron's
KOD Stock Explodes As Phase 3 Countdown Draws Wall Street Firepower - StocksToTrade
KOD Stock Explodes As Phase 3 Catalyst Frenzy Draws Wall Street - timothysykes.com
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha
Jefferies cuts Kodiak Sciences stock price target on valuation review By Investing.com - Investing.com Nigeria
Jefferies cuts Kodiak Sciences stock price target on valuation review - Investing.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday - Benzinga
Kodiak Sciences (KOD) Surges 156% After Positive Phase 3 DAYBREA - GuruFocus
KOD Maintained by HC Wainwright & Co. -- Price Target Raised to $96 - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial - Yahoo Finance
KOD Stock Explodes As Phase 3 Catalyst Frenzy Hits - timothysykes.com
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint ResultsSlideshow - Seeking Alpha
Kodiak skyrockets on positive study data for 2 eye drugs - BioPharma Dive
Kodiak Sciences (KOD) Shares Soar 145% on Positive Phase 3 Trial Results for Zenkuda - GuruFocus
Kodiak Sciences options flow after positive Phase 3 DAYBREAK AMD trial data - Investing.com
Kodiak’s stock rallies on Phase III wAMD success - Yahoo Finance
AMD phase III docks at Kodiak treasure island - BioWorld News
Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study Results - GuruFocus
Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win - TIKR.com
Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trial - Seeking Alpha
Why Is Regeneron Pharmaceuticals Stock Falling Today?Regeneron Pharmaceuticals (NASDAQ:REGN), Kodiak S - Benzinga
New Real-Time Market Updates on YouTube Spotlight Kodiak Sciences Inc (KOD) - GuruFocus
Kodiak Sciences Inc Azioni (KOD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kodiak Sciences Inc Azioni (KOD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Sep 29 '26 |
Buy |
85.05 |
33,726 |
2,868,255 |
20,191,214 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
83.58 |
418,323 |
34,963,077 |
19,515,907 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
72.57 |
807,840 |
58,625,708 |
19,121,134 |
| PERLROTH VICTOR | Chairman and CEO |
Sep 25 '26 |
Option Exercise |
4.20 |
1,280,524 |
5,381,943 |
3,676,062 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Option Exercise |
1.04 |
30,000 |
31,200 |
241,930 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):